Objective: To explore the clinical efficacy and safety of Naomaili granules in the treatment of acute ischemic stroke. Methods: Eighty-eight patients were randomly divided into a treatment group and a control group, with 44 patients in each group. The control group received conventional Western medicine treatment, while the treatment group was additionally administered Naomaili granules at 10g per time, 3 times per day, for 20 days. Neurological function (NIHSS), activities of daily living (BI), inflammatory factors (hs-CRP, IL-6) levels, and adverse reactions were observed before and after treatment. Results: After 20 days of treatment, the NIHSS score of the treatment group decreased from (9.20 ± 2.10) to (5.12 ± 1.30), the BI index increased from (52.30 ± 8.50) to (78.60 ± 9.20), and hs-CRP and IL-6 decreased to (3.12 ± 1.10) mg/L and (18.20 ± 4.20) pg/mL, respectively, all significantly better than the control group (P < 0.01). The incidence of adverse reactions in the treatment group was 4.55%, lower than the 15.91% in the control group (P < 0.05). Conclusion: Naomaili granules can improve neurological function and living ability, reduce inflammatory response, and have good safety in patients with acute ischemic stroke.
Wang B, Wang X, 2024, Clinical Efficacy Analysis of Yangxue Qingnao Granules as Adjuvant Therapy for Acute Cerebral Infarction. Journal of Hebei North University (Natural Science Edition), 40(10): 32–34.
Zhao L, Liu H, 2024, Effect of Naomaili Granules Combined with Butylphthalide Soft Capsules in the Treatment of Acute Cerebral Infarction and Its Influence on Hemorheological Indexes of Patients. Reflexotherapy & Rehabilitation Medicine, 5(21): 17–20.
Qian Q, Zhang J, Bian W, et al., 2023, Effects of Naomaili Granules on Neurological Function, Hemorheology, and Serological Indexes in Patients with Acute Cerebral Infarction. Jilin Journal of Traditional Chinese Medicine, 43(9): 1042–1046.
Jiang C, Wang T, Li M, et al., 2023, Clinical Efficacy of Naomaili Granules in Treating Acute Cerebral Infarction with Unilateral Visual Field Defect as the First Symptom. Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, 21(4): 735–738.
Cao Y, Wang Q, He D, 2023, Clinical Efficacy and Mechanism of Naomaili Granules Combined with Urinary Kallidinogenase in the Treatment of Acute Cerebral Infarction. Shandong Medical Journal, 63(16): 64–66.
He W, 2023, Effect of Naomaili Granules Combined with Alteplase Intravenous Thrombolysis in the Treatment of Acute Cerebral Infarction. Medical Journal of Chinese People’s Health, 35(12): 78–81.
Zhang M, Sun J, Guo H, et al., 2020, Clinical Observation on the Efficacy of Naomaili Granules in the Treatment of Different Subtypes of Acute Cerebral Infarction. Journal of Apoplexy and Nervous Diseases, 37(7): 638–640.
Wang T, Geng S, Zhang L, et al., 2024, Effects of Naomaili Granules Combined with Edaravone Dexborneol Injection on Neurological Function, Hemorheology, and Oxidative Stress in Patients with Acute Cerebral Infarction. Progress in Modern Biomedicine, 24(6): 1077–1081.